VS

Vivek Singh

Active Director Director DIN 09014652
DIN 09014652 First appointment Dec 2020 Primary industry E-Commerce
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Dec 2020
Shareholding value β€’β€’β€’β€’ Premium profile

About Vivek Singh

Data last updated:

Vivek Singh is a Director at Genox Pharmaceuticals Private Limited (since 2020). The company operates in E-Commerce.

DIN 09014652
Primary Designation Director
Industry E-Commerce
First Appointment 30 Dec 2020
Oldest Company Age 5 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director30 Dec 20202020Active

Board colleagues of Vivek Singh

NameDINCompanyDesignation
Ashish Dalmia09014651Genox Pharmaceuticals Private LimitedDirector

Directorship timeline

Open interactive timeline →
Genox Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Vivek Singh

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Vivek Singh

Vivek Singh currently holds 1 directorship: Genox Pharmaceuticals Private Limited (Director, since 30 Dec 2020).

Vivek Singh was first appointed on 30 Dec 2020 as Director at Genox Pharmaceuticals Private Limited.

The current boards of Vivek Singh's companies include Ashish Dalmia (Genox Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available